Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Hypertension

Empagliflozin Heart Failure Study Meets Primary End Point

Brian Park, PharmD

August 4, 2020

The double-blind EMPEROR-Reduced trial enrolled 3730 adults with HFrEF, with and without diabetes.

Chronic Kidney Disease (CKD)

Orphan Drug Status Granted to Potential Polycystic Kidney Disease Treatment

Brian Park, PharmD

August 4, 2020

Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.

Chronic Kidney Disease (CKD)

Trial Investigating Dapagliflozin in CKD Meets All End Points

Brian Park, PharmD

August 3, 2020

The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.

Hypertension

FDA to Review Furosemide Formulation Delivered Via On-Body Infusor

Brian Park, PharmD

July 31, 2020

Furoscix is an investigational, proprietary, pH-neutral formulation of furosemide designed for subcutaneous administration via a wearable, pre-programmed on-body drug delivery system for outpatient self-administration.

Lupus Nephritis

Voclosporin Granted Priority Review for Lupus Nephritis

Brian Park, PharmD

July 27, 2020

The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.

Transplantation

Avacopan NDA Submitted for ANCA-Associated Vasculitis

Brian Park, PharmD

July 15, 2020

ChemoCentryx, Inc has submitted a NDA to the Food and Drug Administration (FDA) for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Men's Health Update

Siltuximab to Be Evaluated for COVID-19 Associated ARDS in Phase 3 Trial

Brian Park, PharmD

July 6, 2020

Siltuximab is currently marketed under the trade name Sylvant and is indicated for the treatment of multicentric Castleman’s disease.

Men's Health Update

COVID-19 Vaccine Candidate Looks Promising in Early Human Trial

Brian Park, PharmD

July 2, 2020

Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.

Bladder Cancer

Bavencio Approved for First-Line Urothelial Carcinoma Maintenance Treatment

Brian Park, PharmD

July 2, 2020

The FDA has approved Bavencio® (avelumab; EMD Serono) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

Hypertension

Sacubitril/Valsartan Under Review for Heart Failure With Preserved Ejection Fraction

Brian Park, PharmD

June 26, 2020

The FDA has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsartan (Entresto; Novartis) in the treatment of heart failure with preserved ejection fraction.

Next post in Hypertension